Slide 1: FY25 Results Presentation
FY25 RESULTS PRESENTATION 28 August 2025 Samantha Cheetham CEO John Slaviero CFO/COO
Slide 2: Agenda
AGENDA Performance Highlights FY25 Financial Results Business Update Strategy and Outlook
Slide 3: FY25 Performance Highlights
FY25 PERFORMANCE HIGHLIGHTS Improved operational efficiencies continue to drive strong margin growth FINANCIAL BUSINESS Revenue of $110.4m Revenue flat with mix of regional (- 0.7% pcp) performance 62.9% Gross Profit Margin (+80 New machinery, product and bps) geographical mix boosts gross margin EB
Slide 4: Sales by Business Unit
SALES BY BUSINESS UNIT Good European and Brazilian Growth offset by weaker Direct Exports SALES BY BUSINESS UNIT (AUD MILLIONS) BUSINESS UNIT % SALES $130 50% $120 $107.9 $111.2 $110.4 41% 37% $110 $95.2 8.8 8.6 40% 34% 35% 34% $100 9.1 31% $90 $81.6 7.3 30% 25% 23% 24% $80 $67.4 5.4 36.9 41.3 44.7
Slide 5: Sales by Region
SALES BY REGION Strong European regional performance SALES BY REGION (AUD MILLIONS), % GROWTH PCP SALES BY REGION (AUD MILLIONS) $60 Europe North America $47.7m, +11.0% $50 $24.3m, -1.5% $40 Middle East & Africa $8.0, -29.3% $30 $20 South America $11.8m, -6.3% APAC $18.6, -5.5% $10 $0 FY20 FY21 FY22
Slide 6: Sales by Product Category
SALES BY PRODUCT CATEGORY Aesthetics & Whitening continued strength with Amalgam declines continuing SALES BY CATEGORY (AUD millions) CATEGORY AS % SALES $120 $111.2 $110.4 60% $107.9 52% $110 50% $95.1 6.5 6.2 46% 45% 47% $100 6.5 50% 45% $90 $81.6 6.8 31.0 32.0 31.3 40% $80 32% $67.3 6.0 29.8 31%
Slide 7: Financial Performance
FINANCIAL 4 PERFORMANCE Q
Slide 8: Profit and Loss
PROFIT AND LOSS • Total sales of $110.4m (down 0.7% on pcp) Profit & Loss (#039;000) FY25 FY24 % Change Revenue • Growth in European and Brazilian 110,384 111,206 -0.7% Sales Revenue markets, offset by weaker Middle Cost of goods sold -41,006 -42,168 -2.8% Gross Profit 69,378 69,038 0.5% Eastern and As
Slide 9: Balance Sheet
BALANCE SHEET o Unused working capital bank facilities of Balance Sheet (#039;000) Assets FY25 FY24 $10.0 million, $23 million of unused building Cash & cash equivalents 8,981 6,275 construction facility and $9.0 million cash in Trade & other receivables 20,886 21,045 bank Inventories 27,788 28,748 3,0
Slide 10: Cash Flow
CASH FLOW • Operating cashflow up strongly, boosted by Cash Flow (#039;000) FY25 FY24 Receipts from customers 112,769 111,938 • Reduction in working capital -88,693 -93,810 Payments to suppliers & employees • Normalised growth in operating Interest received 15 19 Interest & other finance costs paid -1,
Slide 11: Business Update
BUSINESS UPDATE
Slide 12: Operational Update
OPERATIONAL UPDATE • Stela progressing well, receiving great feedback from industry opinion leaders • FY25 Stela sales have reached $2.5 million in sales • Continued investment in equipment to achieve operational efficiencies and manage new and existing product growth Composite Syringe Machine Proje
Slide 13: SDI – ESG Roadmap
SDI – ESG ROADMAP FY25 FY26-FY27 Additional ESG actions “Complying” “Enhancing” completed in FY25 Review top suppliers on ESG Review initiatives for emission risks and incorporate into an reduction actions/strategies, AASB S2 Gap Analysis updated Modern Slavery including how this reflects on a
Slide 14: Strategy & Outlook
STRATEGY & OUTLOOK
Slide 15: Project Montrose
PROJECT MONTROSE • Montrose Project Update • Construction tenders received around $26 million • Due diligence in progress on preferred tender. • The planning permit is expected to be received in Sept 25. • The project will be fully funded by a combination of sale and lease back of the current Bayswa
Slide 16: Project Montrose
PROJECT MONTROSE Nov 2024 – April 2025 – Feb 2026 – Feb 2027 – Final Design Tendering Commence Commence completed Works Stage Construction Relocation Dec 2024 – Sep 2025 – Jan 2027 – Dec 2027 – Planning Expected Construction Relocation Permit Planning / Fit out Completed Submitted Approval Completed
Slide 17: Strategy & Outlook
STRATEGY & OUTLOOK o Aesthetics and Whitening products continue to be the focus for new product development • Stela exceeding expectations, on track to be one of our best product launches o Achieve manufacturing and logistic efficiencies through new site to help achieve sales of +$200m o Investment
Slide 18: Q&A
Q&A
Slide 19: Appendices
APPENDICES \y.® g d rs
Slide 20: Awards
AWARDS • Winner of the 2023 Australian Export Award for International Health • Winner of the 2024 Victorian Export Award for International Health (3rd year in a row)
Slide 21: Strategy
STRATEGY PRIORITY 1 High quality market leading products SDI will focus its sales, marketing and innovation efforts on its Riva, composites, cements and Pola brands. This targeted innovation will deliver incremental sales growth and act as a gateway to introduce clinicians to SDI’s full portfolio. P
Slide 22: Sales Analysis
SALES ANALYSIS Product Category ($m) FY20 FY21 FY22 FY23 FY24 FY25 Aesthetics 30.9 36.6 43.2 51.1 55.3 57.8 Whitening 18.1 26.5 29.8 31.3 31.0 32.0 Amalgam 13.2 12.5 15.3 19.0 18.4 14.4 Equipment 5.1 6.0 6.8 6.5 6.5 6.2 Region ($m) FY20 FY21 FY22 FY23 FY24 FY25 North America 14.6 20.4 22.1 25.6 24.7
Slide 23: Important Notice & Disclaimer
Important Notice & Disclaimer This Presentation contains summary information about SDI Limited (SDI) and its subsidiaries and their activities. The information in this Presentation does not purport to be complete. It should be read in conjunction with SDI’s other periodic and continuous disclosure a